Tilray | TRLY - Cash And Equivalent

Stock Price
8.96
Daily Change
-0.44 -4.68%
Monthly
7.31%
Yearly
1,237.31%
Q2 Forecast
9.04

Tilray reported $264.83M in Cash and Equivalent for its fiscal quarter ending in June of 2025.





Cash And Equivalent Change Date
Acasti Pharma USD 16.86M 3.14M Sep/2025
Akebia Therapeutics USD 184.84M 18.4M Dec/2025
Alaunos Therapeutics USD 1.94M 941K Sep/2025
Aurora Cannabis CAD 56.36M 39.33M Dec/2025
Avita Medical AUD 10.24M 1.98M Dec/2025
Canopy Growth CAD 371.32M 73.26M Dec/2025
Cronos Group USD 791.79M 7.62M Dec/2025
Dianthus Therapeutics USD 51.09M 4.9M Dec/2025
Divis Laboratories Ltd INR 4.15B 31.87B Mar/2025
Ionis Pharmaceuticals USD 2.68B 437M Dec/2025
IQVIA Holdings USD 1.98B 166M Dec/2025
Knight Therapeutics CAD 76.45M 5.43M Dec/2025
Moderna USD 2.6B 1.46B Dec/2025
Organigram Holdings CAD 7.58M 20.62M Dec/2025
Organon & Co USD 672M 73M Sep/2025
Revvity USD 919.86M 11.53M Dec/2025
Tectonic Therapeutic USD 253.8M 14.64M Dec/2025
Tilray USD 264.83M 43.16M Jun/2025
Viatris USD 1.32B 347.1M Dec/2025
Xeris Pharmaceuticals USD 111.04M 19.44M Dec/2025
Zealand Pharma A/S 4.58B 1.4B Dec/2025